A Phase 1/2 interventional study of Investigational Influenza Vaccine and Investigational COVID-19 Vaccine in Influenza and COVID-19 (Coronavirus Disease 2019), sponsored by BioNTech SE. Completed at 31 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by BioNTech SE · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.
Among the 966 studies in Influenza, Human with a site in United States, this one is the 124th largest by enrollment of the 843 interventional ones that give a count, is one of 29 that started in 2025, is one of 72 in phase 1/2, and was the 916th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–55 · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
David Moss · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
966 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 249 · Phase 2 244 · Phase 3 127 · Phase 4 147
First in 1997; this study’s year is marked. 29 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,650 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 270 across the 843 interventional studies, 261 across the 122 observational. Of the 841 that completed or were terminated, 433 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
435 of 966 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
BioNTech SE has 5 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
41 of the studies in Influenza, Human with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496450Phase 3ModernaTX, Inc.A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | 2027-01-28 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT07159763Phase 3Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | 2027-07-02 |
| NCT07851246Phase 3GlaxoSmithKlineA Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | 2027-07-09 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 41 to your calendar (.ics) → With an account.
Among the 966 studies in Influenza, Human with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together.
This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Refer to the study contact for further eligibility details
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low Dose COVID-19 Vaccine (1a)
Biological: Investigational COVID-19 Vaccine
Low Dose COVID-19 Vaccine ( 1b)
Biological: Investigational COVID-19 Vaccine
Low Dose COVID-19 Vaccine ( 1c)
Biological: Investigational COVID-19 Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 1)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (Medium Dose Combination 2)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 3)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 4)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Licensed COVID-19 Vaccine
Biological: Licensed COVID-19 Vaccine
Licensed Influenza Vaccine (1)
Biological: Licensed Influenza Vaccine 1
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 5)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 6)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 7)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Licensed COVID-19 Vaccine
Biological: Licensed COVID-19 Vaccine
Licensed Influenza Vaccine (2)
Biological: Licensed Influenza Vaccine 2
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 6)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 4)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 7)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (Medium Dose Combination 2)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 3)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Licensed COVID-19 Vaccine
Biological: Licensed COVID-19 Vaccine
Licensed Influenza Vaccine (3)
Biological: Licensed Influenza Vaccine 3
Licensed Influenza Vaccine (2)
Biological: Licensed Influenza Vaccine 2
Low Dose COVID-19 Vaccine ( 1b)
Biological: Investigational COVID-19 Vaccine
Low Dose COVID-19 Vaccine ( 1c)
Biological: Investigational COVID-19 Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 4)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 7)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (Medium Dose Combination 2)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 3)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Investigational Influenza and COVID-19 Combination Vaccine (High Dose Combination 5)
Combination Product: Investigational Influenza and COVID-19 Combination Vaccine
Medium Dose Investigational Influenza Vaccine (1)
Biological: Investigational Influenza Vaccine
High Dose Investigational Influenza Vaccine (2)
Biological: Investigational Influenza Vaccine
Licensed COVID-19 Vaccine
Biological: Licensed COVID-19 Vaccine
Licensed Influenza Vaccine (3)
Biological: Licensed Influenza Vaccine 3
Investigational Influenza Vaccine
Investigational COVID-19 Vaccine
Investigational Combined Influenza and COVID-19 Vaccine
Licensed Influenza Vaccine 1
Licensed Influenza Vaccine 2
Licensed Influenza Vaccine 3
Pfizer-BioNTech COVID-19 Vaccine
Percentage of participants reporting prompted local reactions within 7 days following investigational product administration
Time frame: Day 7
Percentage of participants reporting prompted systemic events within 7 days following investigational product administration
Time frame: Day 7
Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration
Time frame: 1 month
Percentage of participants reporting serious adverse events (SAEs) through 6 months following investigational product administration
Time frame: 6 months
GMTs before and through 1 month following investigational product administration
Time frame: Before vaccination through to 1 month after vaccination
Plan to share: No
Ran from Feb 2025 to primary completion in Dec 2025, 10 months.
Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 10 months is below that.
Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.